Because endogenous NK cells are known to be functionally deficient in MM and may even interplay negatively with CD38 targeting therapies [81], there is a rationale for approaches where allogeneic NK cells are used in combination with already approved therapies (Figure 2). This evidence concerns the gene CD38 and Miyoshi myopathy.